Intuitive Surgical, Inc. $ISRG Shares Sold by Liontrust Investment Partners LLP

Posted by Geri Gentry on Jul 31st, 2026

Liontrust Investment Partners LLP trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 10.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 264,963 shares of the medical equipment provider’s stock after selling 29,342 shares during the quarter. Intuitive Surgical accounts for 1.7% of Liontrust Investment Partners LLP’s portfolio, making the stock its 9th largest holding. Liontrust Investment Partners LLP’s holdings in Intuitive Surgical were worth $122,145,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ISRG. Newbridge Financial Services Group Inc. grew its position in Intuitive Surgical by 300.0% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 44 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 33 shares during the last quarter. Laurel Wealth Advisors LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at about $31,000. Turning Point Benefit Group Inc. raised its position in shares of Intuitive Surgical by 833.3% during the fourth quarter. Turning Point Benefit Group Inc. now owns 56 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 50 shares during the last quarter. Motiv8 Investments LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter valued at about $34,000. Finally, Oakworth Capital Inc. lifted its stake in shares of Intuitive Surgical by 281.2% in the fourth quarter. Oakworth Capital Inc. now owns 61 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: UBS upgraded ISRG, arguing that the selloff has been excessive. The call provides a counterpoint to recent target reductions and may support a rebound thesis as investors refocus on the company’s recurring instrument revenue and installed da Vinci system base. UBS upgrades Intuitive Surgical
Positive Sentiment: Intuitive Surgical is expanding robotic-assisted surgery beyond its traditional urology strength, with general surgery and newer specialties offering additional long-term procedure growth opportunities. Robotic surgery expansion beyond urology
Neutral Sentiment: HSBC downgraded ISRG from Buy to Hold but assigned a $391 price target, implying upside from recent levels. The mixed analyst signals reflect uncertainty about near-term growth rather than a fundamental change to the company’s long-term opportunity.
Neutral Sentiment: Executive Vice President Mark Brosius sold small blocks of shares under a pre-arranged Rule 10b5-1 plan. The transactions totaled roughly $20,000 and reduced his holdings by about 2% in each sale, limiting their significance for investors. Intuitive Surgical insider sale
Negative Sentiment: Investors remain concerned that U.S. procedure growth could soften and that deferred care may weigh on near-term utilization. Those concerns overshadowed the latest quarterly beat, in which revenue rose 18.4% year over year to $2.89 billion and EPS reached $2.80 versus the $2.48 consensus. Intuitive Surgical post-earnings selloff

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $352.97 on Friday. The company’s fifty day moving average is $399.96 and its 200-day moving average is $452.67. Intuitive Surgical, Inc. has a 52 week low of $328.57 and a 52 week high of $603.88. The company has a market capitalization of $124.70 billion, a PE ratio of 40.43, a P/E/G ratio of 2.55 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last announced its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.48 by $0.32. The business had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter last year, the company posted $1.81 EPS. On average, analysts forecast that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Insider Activity at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the sale, the executive vice president directly owned 5,720 shares of the company’s stock, valued at $2,426,080.80. This trade represents a 6.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of Intuitive Surgical stock in a transaction on Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the completion of the transaction, the senior vice president owned 6,463 shares of the company’s stock, valued at approximately $2,718,014.65. The trade was a 46.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 6,606 shares of company stock valued at $2,786,967. Company insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ISRG shares. Wells Fargo & Company restated an “overweight” rating and set a $487.00 price target (down from $654.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. Deutsche Bank Aktiengesellschaft decreased their price objective on Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating on the stock in a report on Tuesday, June 2nd. Citigroup cut their target price on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Royal Bank Of Canada decreased their price target on shares of Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Finally, BTIG Research dropped their price objective on shares of Intuitive Surgical from $512.00 to $469.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Twenty analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $509.02.

View Our Latest Report on ISRG

Intuitive Surgical Company Profile

(Free Report)

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.